Biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis episode artwork

EPISODE · May 23, 2023 · 11 MIN

Biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis

from ehealth radio network · host eHealth Radio Network

    Randy Milby, the Chief Executive Officer and Chairman of Hillstream BioPharma, a biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death, and immuno-oncology targeted novel biologics joins eHealth Radio and the Cancer Information & Health News Channels. Listen to interview with host Eric Michaels and guest Randy Milby discuss the following: Please tell us a bit about your background and Hillstream BioPharma.What developments are currently in Hillstream’s pipeline?How does ferroptosis-targeted therapy differentiate from other cancer treatments currently available or under development?Why is it important to Hillstream to develop drug resistant therapeutics for cancers with few treatment options?What advice can you share with industry peers, key opinion leaders, or anyone pursuing R&D in the biotechnology space?Looking ahead, what exciting advances do you think are on the horizon for Hillstream?Mr. Milby previously served as Chief Executive Officer and Member of the Board of Directors at CorMedix, a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases. He is a seasoned executive who led the increase in market capitalization from $3M to a peak of $350M of Cormedix while improving the company’s financial position with capital raises from equity markets. He oversaw efforts to gain CE Market approval of Neutrolin® in the European Union and held increasing roles of responsibility at Goldman Sachs and Dupont Merck prior in his career.   Website: https://hillstreambio.com  Social Media Links: Facebook: https://facebook.com/HillstreamBioPharma   Linkedin: https://linkedin.com/company/hillstream-biopharma   Twitter: https://twitter.com/HillstreamB  People also listened to this: Checkable Medical: Revolutionizing Home Healthcare and Telemedicine

Episode metadata supplied by the publisher feed · Published May 23, 2023

Embed this episode

NOW PLAYING

Biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis

0:00 11:35

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of ehealth radio network?

This episode is 11 minutes long.

When was this ehealth radio network episode published?

This episode was published on May 23, 2023.

Can I download this ehealth radio network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!